The rollout of 2 major interventions to prevent severe respiratory syncytial virus (RSV) in infants—the RSV prefusion F (RSVpreF; ABRYSVO) vaccine for pregnant individuals and the monoclonal antibody nirsevimab (Beyfortus) for newborns—has shown high uptake in a recent cohort study.1
High vaccine uptake shows promise for infantile respiratory syncytial virus (RSV) prevention. | Image credit: angellodeco – stock.adobe.com
Conducted at a single academic center, the study found that 64% of eligible pregnant individuals received the RSVpreF vaccine, while 70% of eligible infants received nirsevimab before hospital discharge.
This retrospective cohort study is published in JAMA Network Open.
“It is crucial to understand the uptake and outcomes of the newly approved pharmacologic interventions against infant RSV to…